Turk, M. Et Al. 2018. Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE , vol.6, no.4 , 1389-1390.

Turk, M., Kocaturk, E., Cure, K., & YILMAZ, İ., (2018). Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE , vol.6, no.4, 1389-1390.

Turk, MURAT Et Al. "Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria," JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE , vol.6, no.4, 1389-1390, 2018

Turk, MURAT Et Al. "Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE , vol.6, no.4, pp.1389-1390, 2018

Turk, M. Et Al. (2018) . "Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria." JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE , vol.6, no.4, pp.1389-1390.

@article{article, author={MURAT TÜRK Et Al. }, title={Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria}, journal={JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE}, year=2018, pages={1389-1390} }